Decellularized Blood Vessel Closure Using Protein Denaturation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing decellularized tissue production methods cause morphological damage, hindering autologous cell infiltration and graft integration, particularly when suturing is used to close branch portions in blood vessels.
Innovation Solution
A method involving protein denaturation treatment to close excised branch portions in decellularized blood vessels, minimizing damage and facilitating autologous cell infiltration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If suturing is used to close branch portions in decellularized blood vessels, then vessel closure is achieved, but morphological damage occurs and autologous cell infiltration is hindered
Solution Approach 1:
The patent replaces the mechanical suturing system with a chemical protein denaturation system. By applying protein denaturation treatment to the branch portion, the vessel closes through biochemical changes rather than mechanical stitching, thereby avoiding the morphological damage and cell infiltration hindrance caused by sutures.
Solution Approach 2:
The patent changes the closure mechanism from mechanical (suturing) to biochemical (protein denaturation). By altering the physical-chemical state of proteins in the branch portion through denaturation treatment, the vessel achieves closure without the harmful mechanical intervention of suturing.
2Ease of operation
If protein denaturation treatment is used to close branch portions, then autologous cell infiltration is facilitated, but the process complexity increases
Solution Approach 1:
The patent employs protein denaturation treatment to close branch portions, which facilitates autologous cell infiltration by preserving the tissue surface state and reducing morphological damage. This biochemical approach, while adding processing complexity, significantly improves biological compatibility and cell infiltration outcomes.
3Object-affected harmful factors
If decellularization is performed to improve biocompatibility, then graft rejection is reduced, but DNA removal completeness becomes critical
Solution Approach 1:
The patent applies protein denaturation treatment as part of the decellularization process. This treatment helps remove cellular components and DNA while preserving the extracellular matrix structure, thereby achieving complete DNA removal to prevent graft rejection while maintaining tissue integrity for subsequent cell infiltration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Facilitates autologous cell infiltration and functional regeneration of decellularized tissue post-transplantation by preserving the tissue's surface state and reducing morphological damage.
Implementation Method 1
adhering, by a protein denaturation treatment, a portion where a branch has been excised to close the vessel
Data Source
AI summary
A method of producing a decellularized transplantation material, wherein the method includes the steps of (a) harvesting a branch-bearing blood vessel from a vertebrate animal (a donor); (b) decellularizing the blood vessel; and (c) adhering, by a protein denaturation treatment, a portion where a branch has been excised to close the vessel. Also, a graft composition consisting of a biocompatible material that contains the decellularized transplantation material.